Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU
LhcCoutinho / Pixabay

Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

According to a story from BioSpace, Chugai Pharmaceutical Co., Ltd. has recently announced that the Marketing Authorisation Application for the its drug satralizumab has been accepted by the European Medicines…

Continue Reading Marketing Applications for a Possible Neuromyelitis Optica Spectrum Disorder Drug Have Been Accepted in the US and EU

Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

The number of systemic juvenile idiopathic arthritis patients who develop lung disease (sJIA-LD) is rising in both the U.S., Europe, the Middle East, and Canada. This trend has been notable…

Continue Reading Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease
VACTERL Association Takes the Life of a Six Year Old Only Five Days After Her Sister was Born
webandi / Pixabay

VACTERL Association Takes the Life of a Six Year Old Only Five Days After Her Sister was Born

According to a story from Express Digest, young mom Emily Nixon, age 25, was heartbroken when her oldest daughter Darcy Roger, age 6, passed away only five days after her…

Continue Reading VACTERL Association Takes the Life of a Six Year Old Only Five Days After Her Sister was Born
“I First Have to Explain it to the Doctors:” Tetrasomy X, a Rare Patient Story From the Czech Republic
DanielCubas / Pixabay

“I First Have to Explain it to the Doctors:” Tetrasomy X, a Rare Patient Story From the Czech Republic

Little Rozárka’s mother isn’t giving up. Her daughter is the only person in the Czech Republic with tetrasomy X, and is one of 50 people in the world with the…

Continue Reading “I First Have to Explain it to the Doctors:” Tetrasomy X, a Rare Patient Story From the Czech Republic

Preclinical Findings for Phenylketonuria and Metachromatic Leukodystrophy Gene Therapies Look Promising

According to a story from BioSpace, the genetic medicines company Homology Medicines, Inc., has recently released preclinical data supporting the development of two experimental gene therapies. One, called HMI-202, is…

Continue Reading Preclinical Findings for Phenylketonuria and Metachromatic Leukodystrophy Gene Therapies Look Promising

The First Clinical Evidence that the Drug Mavoglurant Improves Responsiveness in Fragile X Syndrome (FXS)

Results of a study reported in PLOS ONE that was conducted by a team of scientists indicate that the experimental drug mavoglurant improves responsiveness and eye gaze for patients with…

Continue Reading The First Clinical Evidence that the Drug Mavoglurant Improves Responsiveness in Fragile X Syndrome (FXS)

First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease

Actus Therapeutics, a privately held portfolio company of AskBio, has recently announced through PRWeb, the initiation of patient dosing in a clinical trial testing its investigational gene therapy ACTUS-101. About Pompe…

Continue Reading First Patient to Receive Gene Therapy in a Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease